Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 2, 2008

Sepracor In-Licenses Phase III Epilepsy Drug from Bial for $75M Upfront

  • Sepracor exclusively licensed Bial's antiepileptic compound for development and commercialization in the U.S. and Canada. Bial could make over $175 million through this deal.

    Bial will receive $75 million upfront. The company may also earn milestone-based payments totaling $100 million. Sepracor will be responsible for filing the NDA, seeking marketing approval from the FDA, and commercialization. Sepracor anticipates that the NDA will be submitted in late 2008 or early 2009.

    Bial will also earn compensation for providing finished product to Sepracor. The firm may also receive milestone fees upon FDA approval of the compound in additional indications.

    BIA 2-093 has reportedly been designed to offer patients suffering with partial epilepsy additional control of their seizures and improved quality of life.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »